Passa al contenuto
Merck
Tutte le immagini(3)

Documenti

C4397

Sigma-Aldrich

Chlorzoxazone

Sinonimo/i:

5-Chloro-2(3H)-benzoxazolone, 5-Chloro-2-hydroxybenzoxazole

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(3)

About This Item

Formula empirica (notazione di Hill):
C7H4ClNO2
Numero CAS:
95-25-0
Peso molecolare:
169.57
Numero CE:
202-403-9
Numero MDL:
MFCD00005717
Codice UNSPSC:
12352200
ID PubChem:
24277702
NACRES:
NA.77

Saggio

≥98% (TLC)

Forma fisica

powder

Colore

white to off-white

Punto di fusione

191-192 °C (lit.)

Solubilità

DMSO: 50 mg/mL, clear

Ideatore

Johnson & Johnson

Temperatura di conservazione

room temp

Stringa SMILE

Clc1ccc2OC(=O)Nc2c1

InChI

1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)
TZFWDZFKRBELIQ-UHFFFAOYSA-N

Informazioni sul gene

human ... KCNN4(3783)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Chlorzoxazone may be used:
  • as a calcium-activated potassium (KCa) channel activator in patch-clamp electrophysiology to test its effect on dendritic hyperexcitability
  • as a substrate for cytochrome P450 2E1 (CYP2E1) enzyme in cultured human hepatocytes
  • as a benzimidazolone compound to test its effect on epithelial sodium (Na+) transport

Azioni biochim/fisiol

Chlorzoxazone inhibits the multisynaptic reflex arcs primarily in the spinal cord and brain subcortical areas. It is an activator of calcium activated potassium channels and may contribute to the aortic artery relaxation in mice. Chlorzoxazone also activates the calcium-activated potassium (KCa) channel and small conductance calcium-activated potassium channels (SK). It is metabolized by cytochrome P450 2E1 (CYP2E1) and serves as a probe for monitoring this enzyme function.
Chlorzoxazone is a skeletal muscle relaxant.

Caratteristiche e vantaggi

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H302,H315,H319,H335

Classi di pericolo

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organi bersaglio

Respiratory system

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

dust mask type N95 (US), Eyeshields, Gloves

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 6

1 of 6

Tolbutamide analytical standard

Supelco

T0891

Tolbutamide

Bupropion Hydrochloride Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1730

Bupropion Hydrochloride

Sulfaphenazole ≥98%

Sigma-Aldrich

S0758

Sulfaphenazole

Coumarin ≥99% (HPLC)

Sigma-Aldrich

C4261

Coumarin

Umbelliferone 99%

Sigma-Aldrich

H24003

Umbelliferone

L-Penicillamine 99%

Sigma-Aldrich

196312

L-Penicillamine

Cyrus Ghobadi et al.
Clinical pharmacokinetics, 50(12), 809-822 (2011-11-18)
The maintenance dose of a drug is dependent on drug clearance, and thus any biochemical and physiological changes in obesity that affect parameters such as cardiac output, renal function, expression of drug-metabolizing enzymes and protein binding may result in altered
F Woodward Hopf et al.
Biological psychiatry, 69(7), 618-624 (2011-01-05)
Alcoholism imposes a tremendous social and economic burden. There are relatively few pharmacological treatments for alcoholism, with only moderate efficacy, and there is considerable interest in identifying additional therapeutic options. Alcohol exposure alters SK-type potassium channel (SK) function in limbic
Yong-Long Han et al.
Journal of ethnopharmacology, 139(1), 104-109 (2011-11-15)
Herba Erigerontis injection (HEI), one of the most popular herbal prescription in China, is made from the aqueous extracts of Erigeron breviscapus whole plant. Now HEI is widely used for the treatment of cardiovascular diseases and cerebrovascular diseases such as
Karina Alviña et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 30(21), 7249-7257 (2010-05-28)
Episodic ataxia type-2 (EA2) is an inherited movement disorder caused by mutations in the gene encoding the Ca(v)2.1alpha1 subunit of the P/Q-type voltage-gated calcium channel that result in an overall reduction in the P/Q-type calcium current. A consequence of these
Karina Alviña et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 30(21), 7258-7268 (2010-05-28)
Episodic ataxia type 2 (EA2) is a hereditary cerebellar ataxia associated with mutations in the P/Q-type voltage-gated calcium (Ca(2+)) channels. Therapeutic approaches for treatment of EA2 are very limited. Presently, the potassium (K(+)) channel blocker 4-aminopyridine (4-AP) constitutes the most
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.